title: Treatment of osteonecrosis of the jaw (ONJ) by medical ozone gas insufflation. A case report.
abstract: Osteonecrosis of the jaw (ONJ) is an adverse event reported in patients receiving cancer treatment, especially bisphosphonates and denosumab. A patient with multiple myeloma who underwent up to 22 intravenous zoledronic acid infusions without previous dental examination developed a devastating ONJ lesion in the right horizontal mandibular ramus. He was treated with local ozone gas applications every third day by means of a special bell to avoid O(3) diffusion. Azithromycin 500 mg/day was administered for 10 days prior to the O(3) applications. O(3) therapy resulted in sequestration of the necrotic bone after a median of 15 applications, following which surgery was necessary to remove it. Interestingly, removal was possible without the resection of the healthy mandible edge because of the presence of the bone sequestrum. Medical O(3) gas administration was effective and safe in a patient treated with bisphosphonates who developed a >2.5 cm ONJ lesion. Future research is needed to demonstrate the efficacy and tolerability of such treatment in a larger number of patients.
authors: Supportive Care in Cancer Uni, Istituto Nazionale Tumori, Milan, Italy. carla.ripamonti@istitutotumori.mi.it
authors: Carla Ida
authors: CI
authors: Ripamonti
authors: Massimo
authors: M
authors: Maniezzo
authors: Maria Adelaide
authors: MA
authors: Pessi
authors: Stefania
authors: S
authors: Boldini
mesh_terms: D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D059266:Bisphosphonate-Associated Osteonecrosis of the Jaw / Q000175:diagnosis* / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000009:adverse effects*; D004164:Diphosphonates / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage / Q000009:adverse effects*; D007262:Infusions, Intravenous; D007327:Insufflation; D008297:Male; D008334:Mandible / Q000187:drug effects* / Q000473:pathology*; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000556:secondary*; D010126:Ozone / Q000008:administration & dosage*; D000077211:Zoledronic Acid
chemical_list: D000900:Anti-Bacterial Agents; D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D010126:Ozone; D000077211:Zoledronic Acid